Olmeslide AZ 8/20 Tablet contains Olmesartan Medoxomil 20mg, an angiotensin II receptor antagonist that reduces vasoconstriction and fluid retention, and Azelnidipine 8mg, a long-acting calcium channel blocker that promotes vasodilation. This dual combination provides synergistic blood pressure reduction in patients with hypertension.
Clinically, it is indicated for essential hypertension and patients requiring combination therapy to achieve optimal blood pressure control, particularly in cases where monotherapy is insufficient. The combination ensures effective systolic and diastolic pressure management.
The tablet formulation ensures consistent bioavailability, accurate dosing, and reliable therapeutic outcomes, making it suitable for hospital pharmacies, cardiology clinics, outpatient departments, and specialty pharmacies. It supports better patient adherence with once-daily dosing.
Olmeslide AZ 8/20 Tablet helps in reducing cardiovascular risk, preventing organ damage due to high blood pressure, and improving overall hemodynamic stability. With its proven clinical efficacy and safety under medical supervision, it is a trusted antihypertensive therapy for long-term hypertension management.